Research programme: fibrosis therapeutics - Excaliard Pharmaceuticals

Drug Profile

Research programme: fibrosis therapeutics - Excaliard Pharmaceuticals

Alternative Names: Anti-fibrotic antisense drugs - Excaliard Pharmaceuticals

Latest Information Update: 29 Mar 2012

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Excaliard Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Fibrosis; Scars

Most Recent Events

  • 29 Mar 2012 No development reported for Fibrosis in USA (unspecified route)
  • 29 Mar 2012 No development reported for Scars in USA (unspecified route)
  • 02 Dec 2011 Excaliard Pharmaceuticals has been acquired by Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top